Aprotinin--still courting controversy.
Hausenloy
Derek J
DJ
The Hatter Cardiovascular Institute, University College London Hospital and Medical School, London WC1E 6HX, UK. d.hausenloy@ucl.ac.uk
Pagano
Domenico
D
Keogh
Bruce
B
D007611:Aprotinin / Q000009:adverse effects* / Q000627:therapeutic use; D006348:Cardiac Surgical Procedures / Q000401:mortality; D001026:Coronary Artery Bypass; D047549:Coronary Artery Bypass, Off-Pump; D006490:Hemostatics / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007668:Kidney / Q000187:drug effects; D011358:Product Surveillance, Postmarketing; D051437:Renal Insufficiency / Q000139:chemically induced*; D015842:Serine Proteinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use
D006490:Hemostatics; D015842:Serine Proteinase Inhibitors; D007611:Aprotinin